<DOC>
	<DOCNO>NCT01350804</DOCNO>
	<brief_summary>The core extension study assess safety efficacy secukinumab add background therapy patient active rheumatoid arthritis intolerant inadequate response anti-TNF-α agent . Patients receive either secukinumab , placebo abatacept ( active comparator ) . The core study complete . However , extension study prematurely terminate primary endpoint analysis core study week 24 demonstrate numerically high efficacy active comparator abatacept compare secukinumab .</brief_summary>
	<brief_title>Efficacy 24 Weeks Safety , Tolerability Long Term Efficacy Secukinumab ( AIN457 ) Patients With Active Rheumatoid Arthritis ( RA ) Inadequate Response Anti-Tumor Necrosis Factor α ( Anti-TNFα ) Agents ( CAIN457F2309 CAIN457F2309E1 )</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<criteria>Male nonpregnant , nonlactating female patient Presence RA classify ACR 2010 revise criterion least 3 month screen At Baseline : Disease activity criterion define &gt; = 6 tender joint 68 &gt; = 6 swollen joint 66 WITH least 1 follow screening : AntiCyclic Citrullinated Peptide ( AntiCCP ) antibodies positive OR Rheumatoid Factor positive AND WITH least 1 follow screening : High sensitivity CReactive Protein ( hsCRP ) &gt; = 10 mg/L OR Erythrocyte Sedimentation Rate ( ESR ) &gt; = 28 millimeter ( mm ) /1st hour Patients must take least one antiTNFα agent give approve dose least 3 month randomization experience inadequate response treatment intolerant least one administration antiTNFα agent Patients must take MTX DMARD ( 1 DMARD ) least 3 month randomization stable dose least 4 week randomization ( 7.5 25 mg/week MTX DMARD maximum tolerate dose ) Chest xray evidence ongoing infectious malignant process , obtain within 3 month prior screen evaluate qualified physician RA patient functional status class IV accord ACR 1991 revise criterion Patients ever receive biologic immunomodulating agent except target TNFα Previous treatment celldepleting therapy Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>RA</keyword>
	<keyword>ACR</keyword>
	<keyword>inflammatory joint</keyword>
</DOC>